Author: Pistone, G; Tilotta, G; Gurreri, R; Castelli, E; Curiale, S; Bongiorno, M R
Title: Ocular Surface Disease during dupilumab treatment in patients with atopic dermatitis, is it possible to prevent it? Cord-id: gubi5ojs Document date: 2020_1_27
ID: gubi5ojs
Snippet: Atopic dermatitis (AD) is the most common inflammatory skin disease that affects up to 20% of children and 2-5% of the adult population. This disorder can have a dramatic impact on the quality of life, in fact, negatively affects sleep, productivity, mood, and quality of life. Recently, encouraging results have been obtained with the use of dupilumab. This drug is a human monoclonal antibody directed against the shared α sub-unit of the interleukin (IL)-4 and IL-13 receptor approved for adult p
Document: Atopic dermatitis (AD) is the most common inflammatory skin disease that affects up to 20% of children and 2-5% of the adult population. This disorder can have a dramatic impact on the quality of life, in fact, negatively affects sleep, productivity, mood, and quality of life. Recently, encouraging results have been obtained with the use of dupilumab. This drug is a human monoclonal antibody directed against the shared α sub-unit of the interleukin (IL)-4 and IL-13 receptor approved for adult patients affected by moderate-to-severe AD.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date